Protocol Information

If you are interested in learning more about this study, please call or email the contact person below

Title EVarQuit: Extended pre-quit varenicline to assist in quitting smoking
Description Varenicline (Chantix®) is the best quit smoking medication available, but even with varenicline more than half of people return to smoking within 6 months. The main purpose of this clinical research study is to definitively determine whether extended pre-quit varenicline makes it easier to quit and stay quit.

Participants will be in this research study for approximately 6 months, with active treatment for the first four months and a follow-up visit at 6 months

The research will be conducted at the University at Buffalo South Campus, Diefendorf Hall.

For additional information please visit http://quitforgoodwny.com/

If you're interested in this study, please contact the study coordinator listed below.
Objective We aim to improve smoking cessation rates obtained with varenicline, the best quit smoking agent available, by a simple but theory-based manipulation: increasing the duration of pre-quit varenicline treatment from 1 to 4 weeks.

Keywords: Smoking, smoking cessation, addiction
Principal Investigator HAWK, LARRY
Age Group Adult
Drugs Involved
Clinical Trials.gov
Status Open
Key Eligibility Ages 18-70
Smoking at least 10 cigarettes per day for the last 6 months
Moderately motivated to quit smoking
Disease Group Other; Substance Abuse/Addictions
Treatment Varenicline (Chantix)
Contact LARRY HAWK
+1 716-645-3650
lhawk@acsu.buffalo.edu